January 29, 2013 - Myeloma - The Latest on Research and Treatment from the American Society of Hematology (ASH®) Annual Meeting
- Updates about current and emerging myeloma treatment options
- Updates in myeloma maintenance therapy
- The role of clinical trials in the advancement of myeloma treatment
- Advances in myeloma treatment side effects management
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Questions Asked by the Myeloma Community
- Is there a new study about when treatment should begin for patients diagnosed with multiple myeloma in the smoldering stage?
- If the level of the M-spike protein is not observable, does this indicate myeloma is in remission?
- Do steroid medications and spinal injections affect bone marrow and blood work results for the M-protein?
- What are the chances of pomalidomide (Pomalyst®) being tolerated, if thalidomide (Thalomid®) was not?
- Please comment on T cell and T cell receptor therapy in myeloma. For example, Carl June at Penn.
- Is there a limit to the number of transplants that a patient can have?
- Please discuss maintenance therapy post-stem cell transplant, including when there is a complete response.
- Is it beneficial to reinstate lenalidomide (Revlimid®) maintenance therapy that was started after transplant and was discontinued for fear of getting a secondary cancer?
- If taking lenalidomide (Revlimid®) 25 milligrams, as maintenance, can the dose be decreased? Or, is it safe to stay on this dose indefinitely?
- How do treatments for Myeloma change when the patient also has primary amyloidosis?
- Is central nervous system neuropathy a side effect of bortezomib (Velcade®)? If so, what remedies are effective?
- What do you recommend for a patient with nerve pain following shingles and for preventing shingles in patients with myeloma?
- Are there benefits of utilizing complementary therapies such as acupuncture to help with pain?
- Please comment on the use of curcumin for smoldering myeloma.
Sponsors and Supporters
This program is not sponsored, sanctioned by, or part of the 54th Annual Meeting of the American Society of Hematology (ASH®)